NanoSyrinx closed $13M funding round

NanoSyrinx, a synthetic biology company, closed a financing round of approximately £10 million (c. $13 million). The funding round was co-led by BGF, Octopus Ventures, and M Ventures, with participation from new corporate investor Eli Lilly and Company, and existing investors IQ Capital and Meltwind.

NanoSyrinx is developing a novel platform technology using naturally occurring 'nanosyringes' for the targeted intracellular delivery of biologic therapeutics, including peptide and protein payloads such as functional gene editors and other enzymes, directly to the cytosol of targeted cells. The company intends to use the funds to accelerate the growth of its platform and the development of biologic therapeutics against a pipeline of previously 'undruggable' intracellular targets.